ES2120493T3 - Agentes de contraste que consisten en particulas de galactosa y un acido carboxilico anfifilico. - Google Patents

Agentes de contraste que consisten en particulas de galactosa y un acido carboxilico anfifilico.

Info

Publication number
ES2120493T3
ES2120493T3 ES93902155T ES93902155T ES2120493T3 ES 2120493 T3 ES2120493 T3 ES 2120493T3 ES 93902155 T ES93902155 T ES 93902155T ES 93902155 T ES93902155 T ES 93902155T ES 2120493 T3 ES2120493 T3 ES 2120493T3
Authority
ES
Spain
Prior art keywords
pct
amphyphilic
carboxylic acid
agents consisting
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902155T
Other languages
English (en)
Inventor
Jo Klaveness
Pal Rongved
Lars Stubberud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Application granted granted Critical
Publication of ES2120493T3 publication Critical patent/ES2120493T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

AGENTES DE CONTRASTE QUE COMPRENDEN MICROPARTICULAS DE HIDRATOS DE CARBONO GENERADORAS DE MICROBURBUJAS EN UNA MEZCLA CON UN ACIDO ANFIFILICO QUE CONTIENE UN EXCESO DE 20 ATOMOS DE CARBONO, EXHIBEN UNA BUENA ESTABILIDAD Y/O UN EFECTO DE CONTRASTE MEJORADO Y PUEDEN SER USADOS EN APLICACIONES DE DIAGNOSTICO TALES COMO ULTRASONIDOS Y REPRESENTACION DE IMAGENES MR.
ES93902155T 1992-01-09 1993-01-08 Agentes de contraste que consisten en particulas de galactosa y un acido carboxilico anfifilico. Expired - Lifetime ES2120493T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929200387A GB9200387D0 (en) 1992-01-09 1992-01-09 Improvements in or relating to contrast agents

Publications (1)

Publication Number Publication Date
ES2120493T3 true ES2120493T3 (es) 1998-11-01

Family

ID=10708316

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902155T Expired - Lifetime ES2120493T3 (es) 1992-01-09 1993-01-08 Agentes de contraste que consisten en particulas de galactosa y un acido carboxilico anfifilico.

Country Status (13)

Country Link
US (3) US5567412A (es)
EP (1) EP0620743B1 (es)
JP (1) JP3383954B2 (es)
AT (1) ATE168564T1 (es)
AU (1) AU676146B2 (es)
CA (1) CA2127704A1 (es)
DE (1) DE69319888T2 (es)
DK (1) DK0620743T3 (es)
ES (1) ES2120493T3 (es)
GB (1) GB9200387D0 (es)
HK (1) HK1002102A1 (es)
NO (1) NO306198B1 (es)
WO (1) WO1993013802A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US6875420B1 (en) 1991-09-17 2005-04-05 Amersham Health As Method of ultrasound imaging
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
NZ262237A (en) * 1993-01-25 1997-06-24 Sonus Pharma Inc Ultrasound contrast agents comprising phase shift colloids having a boiling point below the body temperature of the animal it is used in
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4406474A1 (de) 1994-02-23 1995-08-24 Schering Ag Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2189974T3 (es) 1996-09-11 2003-07-16 Imarx Pharmaceutical Corp Procedimientos mejorados para la obtencion de imagenes de diagnostico usando un agente de contraste y un vasodilatador.
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) * 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2345458A1 (en) * 1998-10-12 2000-04-20 Mallinckrodt Inc. Novel ultrasound contrast agents
US6514209B1 (en) 1999-06-07 2003-02-04 Drexel University Method of enhancing ultrasonic techniques via measurement of ultraharmonic signals
EP2286843A3 (en) 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
EP1387637B1 (en) * 2001-04-06 2007-10-31 Bracco Research S.A. Apparatus for measuring local physical parameters in a fluid filled cavity
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
ES2506142T3 (es) 2002-03-01 2014-10-13 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (en) * 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
JP3664401B2 (ja) * 2003-01-22 2005-06-29 独立行政法人科学技術振興機構 Ｎ−グリコシド型糖脂質及びこれから成る中空繊維状有機ナノチューブ
JP2006517558A (ja) * 2003-02-13 2006-07-27 ブラッコ　イメージング　エッセ　ピ　ア コントラスト増強ｘ線位相画像診断
DK2284180T3 (en) 2003-03-03 2015-12-21 Dyax Corp Uses of peptides that specifically bind to the HGF receptor (cMET)
US20040258760A1 (en) * 2003-03-20 2004-12-23 Wheatley Margaret A. Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US9220709B2 (en) * 2006-05-19 2015-12-29 Drexel University Drug loaded contrast agents: combining diagnosis and therapy
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
EP3240579B1 (en) 2014-12-31 2022-07-27 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
TWI832081B (zh) 2016-05-04 2024-02-11 美商藍瑟斯醫學影像公司 用於形成充氣微球體及成像個體之方法、震盪裝置及電腦可讀軟體
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
DE3834705A1 (de) * 1988-10-07 1990-04-12 Schering Ag Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln
DE3313946A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3313947A1 (de) * 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3324754A1 (de) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen Ultraschallkontrastmittel sowie dessen herstellung
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
IN172208B (es) * 1990-04-02 1993-05-01 Sint Sa
US5315997A (en) * 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast

Also Published As

Publication number Publication date
US5567412A (en) 1996-10-22
EP0620743A1 (en) 1994-10-26
DE69319888D1 (de) 1998-08-27
NO942560D0 (no) 1994-07-07
ATE168564T1 (de) 1998-08-15
WO1993013802A1 (en) 1993-07-22
DK0620743T3 (da) 1999-02-01
JPH07505135A (ja) 1995-06-08
AU676146B2 (en) 1997-03-06
DE69319888T2 (de) 1999-02-11
GB9200387D0 (en) 1992-02-26
NO942560L (no) 1994-07-07
HK1002102A1 (en) 1998-07-31
JP3383954B2 (ja) 2003-03-10
AU3348393A (en) 1993-08-03
CA2127704A1 (en) 1993-07-22
NO306198B1 (no) 1999-10-04
EP0620743B1 (en) 1998-07-22
US5614169A (en) 1997-03-25
US5637289A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
ES2120493T3 (es) Agentes de contraste que consisten en particulas de galactosa y un acido carboxilico anfifilico.
EE03079B1 (et) Kontrastaine ja meetod selle valmistamiseks
WO1993013808A3 (en) Improvements in or relating to contrast agents
FI935394A0 (fi) Foerbaettringar i betraeffande kontrastmedel
ES2128412T3 (es) Un producto que contiene dioxido de silicio y un metodo para su preparacion.
NO308126B1 (no) Fosfolipidbasert forbindelse, anvendelse derav samt røntgenkontrastmiddel
SE9404289L (sv) Reglerad frisättning
NO942562L (no) Mikropartikulære kontrastmidler
ES2086771T3 (es) Composicion dermatologica y/o cosmetologica que contiene retinoides.
IT1264690B1 (it) Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
ATE169200T1 (de) Kontrastmittel
GB9115375D0 (en) Compounds
ATE134725T1 (de) Verwendung von fettsäure-2-ethylhexylestern als kaltreinigungsmittel
EA199800881A1 (ru) Способ т1 - взвешенной магниторезонансной визуализации органов ретикуло-эндотелиальной системы
NO974801D0 (no) Koldrengjöringspreparater basert på alkaner eller cykloalkaner og en organisk forbindelse omfattende en ketongruppe
BR9808054A (pt) Método de tratamento e/ou prevenção de diabete melito não-dependente de insulina e composição

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 620743

Country of ref document: ES